Zacks Investment Research upgraded shares of Spero Therapeutics (NASDAQ:SPRO) from a hold rating to a buy rating in a research report released on Tuesday, Zacks.com reports. The firm currently has $12.00 price objective on the stock.
According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. “
Several other brokerages also recently weighed in on SPRO. TheStreet downgraded Tilly’s from a b- rating to a c+ rating in a research report on Tuesday, June 25th. Cantor Fitzgerald restated a buy rating and set a $27.00 price objective on shares of Spero Therapeutics in a research report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Spero Therapeutics currently has an average rating of Hold and a consensus price target of $19.50.
Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.49. Spero Therapeutics had a negative return on equity of 34.34% and a negative net margin of 342.70%. The business had revenue of $7.72 million during the quarter, compared to the consensus estimate of $1.25 million. On average, analysts anticipate that Spero Therapeutics will post -3.06 EPS for the current year.
Institutional investors and hedge funds have recently modified their holdings of the business. Marshall Wace LLP acquired a new position in Spero Therapeutics in the 1st quarter worth about $39,000. Rhumbline Advisers acquired a new stake in shares of Spero Therapeutics in the fourth quarter valued at about $62,000. PNC Financial Services Group Inc. increased its stake in shares of Spero Therapeutics by 58.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 15,800 shares of the company’s stock valued at $98,000 after buying an additional 5,800 shares during the period. IHT Wealth Management LLC acquired a new stake in shares of Spero Therapeutics in the fourth quarter valued at about $115,000. Finally, Virtu Financial LLC acquired a new stake in shares of Spero Therapeutics in the first quarter valued at about $134,000. 46.70% of the stock is owned by institutional investors and hedge funds.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Featured Story: How does inflation affect different investments?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.